Cannabinergic nitrate esters and related analogs

US2016002195A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2016002195-A1
Application numberUS-201414770331-A
CountryUS
Kind codeA1
Filing dateFeb 26, 2014
Priority dateFeb 26, 2013
Publication dateJan 7, 2016
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present technology relates to novel cannabinergic nitrate esters and related analogs, process of preparation, pharmaceutical compositions and their methods of use as medicaments, pharmacological tools and/or biomarkers. The novel cannabinergic nitrate ester compounds provide medicaments useful in treating a variety of diseases and medical disorders.

First claim

Opening claim text (preview).

1 . A compound of formula (I): or a pharmaceutically acceptable salt thereof; wherein: ring C has zero, one, two or three double bonds; X is carbon, CH, N, NH, C(CH 2 ) 2 , S, O, SO, SO 2 , or CF 2 ; R 1 is H, OH, alkyl-OH, ═O, halogen, alkyl, COOH, C(O)Oalkyl, O(CO)alkyl, nitro, ONO 2 , or optionally substituted alkyl, haloalkyl, alkenyl, alkynyl, acyl, aryl, heterocyclyl, heteroaryl, alkoxy, aryloxy, heteroarylalkyl, heteroalkoxy, heteroaryloxy, alkenyl, amino, thio, cyano, thiocynato, isothiocynato, carboxyl, formyl, carbamyl, amino, acylamino, amido, imido, aminoalkyl, aminoaryl, heteroarylamino, heterocyclylamino, sulfonate, sufonamide, sulfonyl, thioalkyl, thioaryl, heteroarylthio, heterocyclylthio, phosphonate, phosphate, or acetate; W is C(CH 3 ) 2 , CH(CH 3 ), C═O, C(O)-alkyl, CF 2 , C═S, C═CH 2 , C(CH 2 ) 2 , spirocyclic ring, S, SO, SO 2 , or C[CH 3 (R 4 )]; R 4 is an optionally substituted alkyl, alkenyl, or alkynyl group; Z is O, S, SO, SO 2 , NH, or N-alkyl; R 2 is H, OH, SH, NH 2 , CF 3 , COOH, alkoxy, halogen, ONO 2 , alkyl-ONO 2 , or optionally substituted alkyl, haloalkyl, amine, amide, imide, alkoxy, alkoxy thio, phosphate, phosphonate, carboxyl, formyl, carbamyl, amino, acylamino, amido, imido, aminoalkyl, aminoaryl, heteroarylamino, heterocyclylamino, sulfonate, sufonamide, sulfonyl, thioalkyl, thioaryl, heteroarylthio, heterocyclylthio, phosphonate, phosphate, or acetate; Y is a bond, C(CH 3 ) 2 , CF 2 , C═O, CH(alkyl), C(alkyl) 2 , C(O)O, NHCO, CONH, alkyl, C(O)Oalkyl, OC(O)alkyl, cycloalkyl, heterocyclyl, lactone, lactam, sultam, O, S, SO, SO 2 , OSO 2 , amine, diazine, alkenyl, or alkynyl group; R 3 is absent, or is O, S, SO 2 , SO 2 NH, NHSO 2 , OSO 2 , OSO 2 alkyl, C(O)Oalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, a carbocyclic, a spirocyclic, heterocyclyl, aryl, heteroaryl, carboxyl, acetate, amine, amide, or imide; V is V 1 or ONO 2 , wherein when any of rings A, B or C comprises a group comprising ONO 2 , V is V 1 , otherwise V is ONO 2 ; and V 1 is H, F, Cl, Br, I, haloalkyl, N 3 , NCS, CN, NO 2 , OH, alkoxy, amino, alkylamino, dialkylamino, trialkylamino, aryl, cycloalkyl, alkyl, alkenyl, alkynyl, —C(O)aryl, —C(O)alkyl, C(O)Oalkyl, —C(O)heteroaryl, —C(O)amino, —C(O)(dialkylamino), C(O)(trialkylamino), C(O)(heterocyclyl), C(O)heteroaryl, —OC(O)alkyl, OSO 2 H, OSO 2 (alkyl), OSO 2 (aryl), OSO 2 NO 2 , OSO 2 (alkyl)CN, OSO 2 (alkyl)OH, OSO 2 alkylamino), —SC(O)alkyl, —SO 2 alkyl, —SO-alkyl, —SC(CH 3 ) 2 C(O)Oalkyl, —SC(CH 3 ) 2 C(O)Oaryl, —SC(CH 3 ) 2 C(O)Oheteroaryl, —SC(CH 3 ) 2 C(O)Oheterocyclyl, Si(alkyl) 3 , —OC(O)aryl, NHC(O)alkyl, NHC(O)aryl, —C(O)H, C(O)Oalkyl, SO 2 (amino), SO 2 (heterocyclyl), SO 2 (trialkylamino), SO 2 (dialkylamino), carbocyclic, a spirocyclic ring, heterocyclyl, heteroaryl, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, boronic acid, boronate ester, BF 3 K, or a biotin group tethered via an amide bond. 2 . (canceled) 3 . The compound of claim 1 , wherein V is ONO 2 . 4 . (canceled) 5 . The compound of claim 4 , wherein R 1 is ONO 2 , alkyl-ONO 2 , O-alkyl-ONO 2 , O—SO 2 -alkyl-ONO 2 , —C(O)O-alkyl-ONO 2 , alkyl-C(O)O-alkyl-ONO 2 , or alkyl-O-alkyl-ONO 2 . 6 . The compound of claim 1 , wherein: ring C has one, two or three double bonds, and at least one double bond is at the C8-C9 position, the C9-C10 position, or the C6a-C10a position; W is C(CH 3 ) 2 , CH(CH 3 ), C═O, or CF 2 ; Z is O or N; and V is H when R 1 is a group comprising ONO 2 , or V is ONO 2 . 7 . The compound of claim 1 , wherein Y—R 3 —V is ONO 2 , alkyl-ONO 2 , O-alkyl-ONO 2 , O—SO 2 -alkyl-ONO 2 , —C(O)O-alkyl-ONO 2 , alkyl-C(O)O-alkyl-ONO 2 , or alkyl-O-alkyl-ONO 2 . 8 - 9 . (canceled) 10 . The compound of claim 1 , wherein: ring C is: ring B is: and V is ONO 2 . 11 . The compound of claim 1 , wherein: ring C has one double bond at the C8-C9 position or the C9-C10 position; W is C(CH 3 ) 2 ; X is carbon; R 1 is H, alkyl, COOH, alkyl-OH; R 2 is OH, O-alkyl, SH, O(CO)alkyl, OC(O)NH 2 , OC(O)NHalkyl, or OC(O)N(alkyl) 2 ; Z is O; Y is alkyl, C(CH 3 ) 2 , or CF 2 ; and V is ONO 2 . 12 . (canceled) 13 . The compound of claim 1 , wherein: ring C is saturated; W is C(CH 3 ) 2 ; X is CH, R 1 is OH, or X—R 1 is C═O; R 2 is OH, O-alkyl, SH, O(CO)alkyl, O(CO)N— Z is O Y is alkyl, C(CH 3 ) 2 , or CF 2 ; V is ONO 2 . 14 . A compound of formula (II): or a pharmaceutically acceptable salt thereof; wherein: ring C is carbocyclic, bicyclic, aryl, heterocyclyl, heteroaryl, or a terpene; ring G is a bond, C═O, NH, CH 2 , CONH, NHCO, OC(O), OCH 2 , S, SO, SO 2 , or O; ring A is an aromatic ring, heteroaromatic ring, heterocyclic ring, or quinone; R 2a and R 2b are each independently H, OH, SH, NH 2 , CF 3 , COOH, alkoxy, halogen, ONO 2 , alkyl-ONO 2 , or optionally substituted alkyl, haloalkyl, amine, amide, imide, alkoxy, alkoxy thio, phosphate, phosphonate, carboxyl, formyl, carbamyl, amino, acylamino, amido, imido, aminoalkyl, aminoaryl, heteroarylamino, heterocyclylamino, sulfonate, sufonamide, sulfonyl, thioalkyl, thioaryl, heteroarylthio, heterocyclylthio, phosphonate, phosphate, or acetate; Y is a bond, C(CH 3 ) 2 , CF 2 , C═O, CH(alkyl), C(alkyl) 2 , C(O)O, NHCO, CONH, alkyl, C(O)Oalkyl, OC(O)alkyl, cycloalkyl, heterocyclyl, lactone, lactam, sultam, O, S, SO, SO 2 , OSO 2 , amine, diazine, alkenyl, or alkynyl group; R 3 is absent, or is O, S, SO 2 , SO 2 NH, NHSO 2 , OSO 2 , OSO 2 alkyl, C(O)Oalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, a carbocyclic, a spirocyclic, heterocyclyl, aryl, heteroaryl, carboxyl, acetate, amine, amide, or imide; V is V 1 or ONO 2 , wherein when ring A or C comprises a group comprising ONO 2 , V is V 1 , otherwise V is ONO 2 ; and V 1 is H, F, Cl, Br, I, haloalkyl, N 3 , NCS, CN, NO 2 , OH, alkoxy, amino, alkylamino, dialkylamino, trialkylamino, aryl, cycloalkyl, alkenyl, alkynyl, —C(O)aryl, —C(O)alkyl, —C(O)heteroaryl, —C(O)amino, —C(O)(dialkylamino), C(O)(trialkylamino), C(O)(heterocyclyl), C(O)heteroaryl, —OC(O)alkyl, OSO 2 H, OSO 2 (alkyl), OSO 2 (aryl), OSO 2 NO 2 , OSO 2 (alkyl)CN, OSO 2 (alkyl)OH, OSO 2 alkylamino), —SC(O)alkyl, —SO 2 alkyl, —SO-alkyl, —SC(CH 3 ) 2 C(O)Oalkyl, —SC(CH 3 ) 2 C(O)Oaryl, —SC(CH 3 ) 2 C(O)Oheteroaryl, —SC(CH 3 ) 2 C(O)Oheterocyclyl, Si(alkyl) 3 , —OC(O)aryl, NHC(O)alkyl, NHC(O)aryl, —C(O)H, C(O)Oalkyl, SO 2 (amino), SO 2 (heterocyclyl), SO 2 (trialkylamino), SO 2 (dialkylamino), a spirocyclic ring, heterocyclyl, heteroaryl, alkylthio, alkylamino, dialkylamino, alkylsulfinyl, alkylsulfonyl, boronic acid, boronate ester, BF 3 K, or a biotin group tethered via an amide bond. 15 - 17 . (canceled) 18 . The compound of claim 14 , wherein: ring C is an aromatic ring; ring A is an aromatic ring; ring G is a bond, C═O, NH, or O; Y is a bond, O, or OSO 2 ; R 2a and R 2b are individually Cl, CN, OH, O-alkyl, alkyl, amino, thio, O(CO)alkyl, OC(O)NH 2 , OC(O)NHalkyl, or OC(O)N(alkyl) 2 ; and V is ONO 2 . 19 . The compound of claim 14 , wherein: C is a carbocyclic group or heterocyclic group; A is a heteroaromatic ring; G is C═O or CONH; Y i

Assignees

Inventors

Classifications

  • Nitro compounds · CPC title

  • Ring systems having three or more relevant rings · CPC title

  • C07D405/04Primary

    directly linked by a ring-member-to-ring-member bond · CPC title

  • Radicals substituted by oxygen atoms · CPC title

  • Ring systems of three rings · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2016002195A1 cover?
The present technology relates to novel cannabinergic nitrate esters and related analogs, process of preparation, pharmaceutical compositions and their methods of use as medicaments, pharmacological tools and/or biomarkers. The novel cannabinergic nitrate ester compounds provide medicaments useful in treating a variety of diseases and medical disorders.
Who is the assignee on this patent?
Univ Northeastern
What technology area does this patent fall under?
Primary CPC classification C07D405/04. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Thu Jan 07 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).